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ABSTRACT 
Following  an  application  from  Pharmatoka,  submitted  pursuant  to  Article  13(5)  of  Regulation  (EC) 
No 1924/2006 via the Competent  Authority of France, the  EFSA Panel on Dietetic Products, Nutrition and 
Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to a 
Urell® product containing cranberry (Vaccinium macrocarpon) juice powder standardised for proanthocyanidins 
(PAC) content and bacterial colonisation of the urinary tract by inhibition of the adhesion of P-fimbriated E. coli 
to uroepithelial cells. The food that is the subject of the health claim is PAC in Urell®. The Panel considers that 
the food constituent, PAC in Urell®, which is the subject of the claim, is sufficiently characterised. The Panel 
considers that reduction of bacterial colonisation of the urinary tract by inhibition of the adhesion of P-fimbriated 
E. coli to uroepithelial cells is a beneficial physiological effect. No human studies from which conclusions could 
be drawn for the scientific substantiation of the claim were provided by the applicant. The Panel concludes that a 
cause and effect relationship has not been established between the consumption of proanthocyanidins in Urell® 
and reduction of bacterial colonisation of the urinary tract by inhibition of the adhesion of P-fimbriated E. coli to 
uroepithelial cells. 
© European Food Safety Authority, 2013 
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SUMMARY 
Following an application from Pharmatoka, submitted pursuant to Article 13(5) of Regulation (EC) 
No 1924/2006 via the Competent Authority of France, the EFSA Panel on Dietetic Products, Nutrition 
and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim 
related to proanthocyanidins in cranberry and reduction of bacterial colonisation of the urinary tract by 
inhibition of the adhesion of P-fimbriated E. coli to uroepithelial cells. 
The scope of the application was proposed to fall under a health claim based on newly developed 
scientific evidence. The application includes a request for the protection of proprietary data. 
The food that is the subject of the health claim is Urell®, a food supplement containing cranberry 
(Vaccinium  macrocarpon)  juice  powder  standardised  for  its  content  in  proanthocyanidins  (PAC). 
The food  constituent  which  is  responsible  for  the  claimed  effect  is  PAC  in  Urell®.  The  Panel 
considers  that  the  food  constituent,  PAC  in  Urell®,  which  is  the  subject  of  the  health  claim,  is 
sufficiently characterised. 
Upon a request by EFSA, the applicant clarified that the claimed effect is “reduction of the bacterial 
colonisation  of  the  urinary  tract”,  and  that  “inhibition  of  the  adhesion  of  P-fimbriated  E.  coli  to 
uroepithelial cells” is the mechanism by which the claimed effect is achieved. The target population 
proposed by the applicant is the general population. The Panel considers that reduction of bacterial 
colonisation of the urinary tract by inhibition of the adhesion of P-fimbriated E. coli to uroepithelial 
cells is a beneficial physiological effect. 
The applicant identified one human intervention study which investigated the effect of Urell® (36 mg 
PAC/capsule) on bacteriuria in vivo (Bianco et al., 2012, a letter to the editor) as being pertinent to 
the claim. The Panel considers that owing to major methodological limitations (i.e. inappropriate urine 
sampling  methods,  inappropriate  handling  of  mixed  microbial  positive  cultures,  and  insufficient 
reporting of the methods used for the identification of pathogenic bacteria), no conclusions can be 
drawn from this study for the scientific substantiation of the claim. 
The applicant also  provided  one  intervention  study  (Botto  and  Neuzillet,  2010)  on  the  effects of 
Urell® in subjects with asymptomatic bacteriuria after radical cystectomy and ileal cystoplasty as 
supportive evidence for the claim. The Panel agrees with the applicant that the results obtained in 
patients with radical cystectomy and ileal cystoplasty cannot be extrapolated to the target population 
(i.e. general population) for this claim. 
In addition, the applicant provided two studies on the ex vivo anti-adherence properties of urine from 
subjects consuming Urell® (Lavigne et al., 2008; Howell et al., 2010) as being pertinent to the claim. 
The Panel considers that these studies do not provide evidence that an inhibition of the adhesion of 
P-fimbriated  E.  coli  to  uroepithelial  cells  in  urine  from  subjects  consuming  PAC  in  Urell®  is 
predictive of the occurrence of a clinically relevant inhibition of the adhesion of P-fimbriated  E. coli 
to uroepithelial cells in humans in vivo. 
The Panel notes that no human studies from which conclusions could be drawn for the scientific 
substantiation of the claim were provided by the applicant. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of proanthocyanidins in Urell® and reduction of bacterial 
colonisation of the urinary tract by inhibition of the adhesion of P-fimbriated E. coli to uroepithelial 
cells. PAC in Urell® and reduction of bacterial colonisation of the urinary tract  
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BACKGROUND 
Regulation (EC) No 1924/2006
4 harmonises the provisions that relate to nutrition and health claims, 
and establishes rules governing the Community author isation of health claims made on foods. As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of this 
Regulation, are authorised in accordance with this Regulation, and are included in the lists of 
authorised  claims provided for in Articles 13 and 14 thereof. In particular, Article 13(5) of this 
Regulation lays down provisions for the addition of claims (other than those referring to the reduction 
of  disease  risk  and  to  children’s  development  and  health)  which  are  based  on  newly  developed 
scientific evidence, or which include a request for the protection of proprietary data, to the Community 
list of permitted claims referred to in Article 13(3). 
According to Article 18 of this Regulation, an application for inclusion in the Community list of 
permitted  claims  referred  to  in  Article 13(3)  shall  be  submitted  by  the  applicant  to  the  national 
competent authority  of a Member  State,  which  will  make  the  application  and  any  supplementary 
information supplied by the applicant available to the European Food Safety Authority (EFSA). 
STEPS TAKEN BY EFSA 
  The application was received on 10/07/2012. 
  The  scope  of  the  application  was  proposed  to  fall  under  a  health  claim  based  on  newly 
developed  scientific  evidence.  The  application  included  a  request  for  the  protection  of 
proprietary data. 
  On 25/07/2012, during the validation process of the application, EFSA sent a request to the 
applicant to provide missing information. 
  On 6/12/2012, EFSA received the missing information as submitted by the applicant. 
  The scientific evaluation procedure started on 12/12/2012. 
  On 27/02/2013, the Working Group on Claims of the NDA Panel agreed on a list of questions 
for the applicant to provide additional information to accompany the application. The clock 
was stopped on 05/03/2013 and restarted on 20/03/2013, in compliance with Article 18(3) of 
Regulation (EC) No 1924/2006. 
  On  23/03/2013,  EFSA  received  the  requested  information  (which  was  made  available  to 
EFSA in electronic format on 22/03/2013). 
  On 24/04/2013, the Working Group on Claims of the NDA Panel agreed on a list of questions 
for the applicant to provide additional information to accompany the application. The clock 
was stopped on 13/05/2013 and restarted on 28/05/2013, in compliance with Article 18(3) of 
Regulation (EC) No 1924/2006. 
  On  28/05/2013,  EFSA  received  the  requested  information  (which  was  made  available  to 
EFSA in electronic format on 22/05/2013). 
  During  its  meeting  on  10/07/2013,  the  NDA  Panel,  having  evaluated  the  data  submitted, 
adopted an opinion on the scientific substantiation of a health claim related to PAC in Urell® 
and reduction of bacterial colonisation of the urinary tract by inhibition of the adhesion of 
P-fimbriated E. coli to uroepithelial cells. 
TERMS OF REFERENCE 
EFSA  is  requested  to  evaluate  the  scientific  data  submitted  by  the  applicant  in  accordance  with 
Article 16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an 
                                                       
4  Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. PAC in Urell® and reduction of bacterial colonisation of the urinary tract  
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opinion on the scientific substantiation of a health claim related to PAC in Urell® and reduction of 
bacterial colonisation of the urinary tract by inhibition of the adhesion of P-fimbriated  E. coli to 
uroepithelial cells. 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation for the marketing 
of PAC in Urell®, a positive assessment of its safety, nor a decision on whether PAC in Urell® is, or is 
not,  classified  as  a  foodstuff.  It  should  be  noted  that  such  an  assessment  is  not  foreseen  in  the 
framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006. PAC in Urell® and reduction of bacterial colonisation of the urinary tract  
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INFORMATION PROVIDED BY THE APPLICANT 
Applicant’s  name  and  address:  Pharmatoka,  S.A.S,  118  avenue  Paul  Doumer,  92563  Rueil 
Malmaison cedex, France. 
Food/constituent as stated by the applicant 
According to the applicant, the food for which this health claim is made is Urell®, a food supplement 
containing cranberry juice powder standardised for proanthocyanidins (36 mg/BL-DMAC/capsule). 
Health relationship as claimed by the applicant 
According to the applicant, the claimed effect is the inhibition of the adhesion of P-fimbriated E. coli 
bacteria to uroepithelial cells. The applicant states that consumption of cranberry products may reduce 
urinary  tract  infections (UTI)  by  preventing  uropathogenic  bacteria  (particularly  Escherichia  coli) 
from  adhering  (sticking)  to  uroepithelial  cells  that line the  wall  of  the  bladder  and thus,  without 
adhesion, Escherichia coli cannot infect the mucosal surface of the urinary tract. 
Wording of the health claim as proposed by the applicant 
The applicant has proposed the following wordings for the health claim: “Proanthocyanidins from 
Urell® contribute to support defence against bacterial pathogens in the lower urinary tract”, “Urell® 
contributes to reduce the P-fimbriated E. coli adhesion to uroepithelial cells”, “Proanthocyanidins 
from Urell® cranberry product contribute to reduce the P-fimbriated E. coli adhesion to uroepithelial 
cells”, “The in vitro and ex vivo studies conducted with Urell® or with urine from subjects who 
consumed  Urell®  show  an  inhibition  of  the  adhesion  of  the  P-fimbriated  E.  coli  bacteria  to 
uroepithelial cells”. 
Specific conditions of use as proposed by the applicant 
The  applicant  has  proposed  an  intake  of  one  tablet  per  day  of  Urell®  supplying  36  mg/day  of 
proanthocyanidins measured by BL-DMAC. The target population proposed is the general population. 
ASSESSMENT 
1.  Characterisation of the food/constituent 
The food that is the subject of the health claim is Urell®, a food supplement containing cranberry 
(Vaccinium macrocarpon) juice powder standardised for its content in proanthocyanidins (PAC). 
The applicant specifies that the food constituent which is responsible for the claimed effect is PAC in 
Urell®. 
PAC  are  a  group  of  flavan-3-ols  ranging  from  dimers  to  polymers.  The  monomeric  flavan-3-ols 
(catechins and epicatechins) are not considered to be PACs. PAC from different sources differ in 
the type of (A or B) linkages between the monomeric units. A capsule of Urell® contains 36 mg of 
PAC  measured  as  procyanidin  A2  equivalents  by  the  colorimetric  4-dimethylaminocinnaldehyde 
(DMAC) method. 
Information  about  the  manufacturing  process,  stability  and  batch-to-batch  variability  has  been 
provided. 
The Panel considers that the food constituent, PAC in Urell®, which is the subject of the health claim, 
is sufficiently characterised. PAC in Urell® and reduction of bacterial colonisation of the urinary tract  
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2.  Relevance of the claimed effect to human health 
The claimed effect proposed by the applicant is “inhibition of the adhesion of P-fimbriated E. coli 
bacteria to uroepithelial cells”. Upon a request by EFSA, the applicant clarified that the claimed effect 
is “reduction of the bacterial colonisation of the urinary tract”, and that “inhibition of the adhesion of 
P-fimbriated E. coli to uroepithelial cells” is the mechanism by which the claimed effect is achieved. 
The target population proposed by the applicant is the general population. 
Bacterial adherence to mucosal surfaces is facilitated by fimbriae, which are proteinaceous fibres on 
the bacterial cell wall (Duguid et al., 1955; Beachey, 1981). Preventing adhesion facilitates urinary 
flushing of the bacteria, and thereby prevents bacterial colonisation of the urinary tract (Foo et al., 
2000). 
The  Panel  considers  that  reduction  of  bacterial  colonisation  of  the  urinary  tract  by  inhibition  of 
the adhesion of P-fimbriated E. coli to uroepithelial cells is a beneficial physiological effect. 
3.  Scientific substantiation of the claimed effect 
The applicant performed a literature search in Medline/Pubmed using the following key words: (i) 
Vaccinium macrocarpon, cranberry, canneberge, (ii) proanthocyanidins, (iii) Escherichia coli, urinary 
tract  infection,  uropathogens.  In  addition,  companies  distributing  preparations  of  Vaccinium 
macrocarpon  were  asked  to  provide  information  about  both  published  and  unpublished  studies. 
A manual search of review articles was also performed. 
The applicant identified one human intervention study which investigated the effect of Urell® (36 mg 
PAC/capsule) on bacteriuria in vivo (Bianco et al., 2012) as being pertinent to the claim. 
The  human  intervention  study  was  published  as  a  letter  to  the  editor  (Bianco  et  al.,  2012)  with 
insufficient information for a full scientific evaluation. EFSA requested the applicant to provide the 
full study report. Instead, the applicant provided additional information on methodological aspects of 
the  study  (i.e.  power  calculations,  methods  of  randomisation,  urine  sample  collection,  steps  for 
performing quantitative urine cultures, statistical methods), and stated that the full study report did not 
exist. The study was a randomised, double-blind, placebo-controlled dose-finding intervention where 
80 female long-term nursing home residents (mean age 89.2 ± 7 years) with history of urinary tract 
infection (UTI) were randomised (20 subjects per group) to consume three capsules of Urell® (108 mg 
PAC), two capsules of Urell® and one placebo capsule (72 mg PAC), one capsule of Urell® and two 
placebo capsules (36 mg PAC), or three placebo capsules (0 mg PAC) for 30 days. Exclusion criteria 
were total incontinence, warfarin therapy, < 4 weeks residence, chronic indwelling catheter, terminal 
prognosis, antibiotic therapy, kidney stones, dialysis, cranberry “therapy”, and cranberry “allergy”. 
The majority of participants were totally dependent on bathing (54 %) and had some bowel (67 %) and 
bladder (76 %) incontinence. Urine samples for urine cultures and analyses were collected at baseline 
and  then  weekly  for  four weeks  (total  5  specimens)  as  catch  specimens.  In  patients  with  urine 
incontinency, a bed pan was placed below them. The Panel notes that the urine sampling methods used 
in this study do not ensure sterility of the samples. Of the 73 urine culture analyses performed at 
baseline,  only  one  had  no  bacterial  growth  and  eight  had  less  than  10
5  cfu/mL.  Subjects  were 
randomised  using  two  strata  permuted  block  randomisation  based  on  the  presence  or  absence  of 
bacterial growth > 10
5 cfu/mL at baseline. The primary outcome of the study was the number of 
episodes of bacteriuria (defined as more than 10
5 cfu/mL of any bacteria) and pyuria (defined as “any 
white blood cells seen on microscopic urin-alysis”) at days 7, 14, 21 and 28 of the study. Results were 
presented and analysed as number of urine samples per intervention groups with “E. coli bacteriuria” 
plus pyuria, with “other bacteriuria” (defined as presence of any pathogen other than E. coli) plus 
pyuria, or with “no growth” (defined as no growth, < 100 000 cfu.mL, > 100 000 cfy/mL but no 
WBCs,  and  growth  of  mixed  flora).  The  Panel  notes  that  mixed  microbial  positive  cultures 
(111/298 cases = 37 %) were treated as no growth, and that no information  was provided on the 
methods used to identify pathogenic bacteria, either in the publication or by the applicant upon a 
request  from  EFSA.  The  Panel  considers  that  owing  to  major  methodological  limitations  (i.e. PAC in Urell® and reduction of bacterial colonisation of the urinary tract  
 
 
8  EFSA Journal 2013;11(7):3326 
inappropriate urine sampling methods, inappropriate handling of mixed microbial positive cultures, 
and  insufficient  reporting  of  the  methods  used  for  the  identification  of  pathogenic  bacteria),  no 
conclusions can be drawn from this study for the scientific substantiation of the claim. 
The applicant also  provided  one  intervention  study  (Botto  and  Neuzillet,  2010)  on  the  effects of 
Urell® in subjects with asymptomatic bacteriuria after radical cystectomy and ileal cystoplasty as 
supportive evidence for the claim. The Panel agrees with the applicant that the results obtained in 
patients with radical cystectomy and ileal cystoplasty cannot be extrapolated to the target population 
(i.e. general population) for this claim. The Panel considers that, in the absence of evidence of an 
effect  of  PAC  in  Urell®  on  bacterial  colonisation  of  the  urinary  tract    in  subjects,  who  are 
representative of the target population, results obtained in patients with radical cystectomy and ileal 
cystoplasty cannot be used for the scientific substantiation of the claim. 
In  addition,  the  applicant  provided  two  ex  vivo  studies  on  the  anti-adherence  properties  of  urine 
obtained from subjects consuming Urell® (Lavigne, 2008; Howell, 2010) as being pertinent to the 
claim. The Panel considers that these studies do not provide evidence that an inhibition of the adhesion 
of P-fimbriated E. coli to uroepithelial cells by urine from subjects consuming PAC in Urell® is 
predictive of the occurrence of a clinically relevant inhibition of the adhesion of P-fimbriated E. coli to 
uroepithelial cells in humans. 
Twelve  ex  vivo  studies  and  eight  reviews  addressing  the  anti-adherence  activity  of  human  urine 
following consumption of cranberry products other than PAC in  Urell® on uropathogenic E. coli 
strains were also provided as supportive evidence. The applicant also referred to 11 published opinions 
regarding cranberry products and urinary tract infections (five opinions of the AFSSA/ANSES, one 
note of the DGCCRF and a study, one guideline of the EAU, one recommendation of the AFSSAPS 
and three opinions of EFSA). The Panel considers that, in the absence of evidence of an in vivo effect 
of PAC in Urell® on bacterial colonisation of the urinary tract, these references cannot be used for 
the scientific substantiation of the claim. 
The Panel notes that several health claims applications on cranberry products standardised by their 
PAC content, in which inhibition of the adhesion of P-fimbriated  E. coli to uroepithelial cells in 
the urine of subjects consuming cranberry products was demonstrated, have already been evaluated by 
EFSA (EFSA, 2009; EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2011, 2013). 
However, the studies provided in these applications did not establish that inhibition of the adhesion of 
P-fimbriated E. coli to uroepithelial cells demonstrated ex vivo predicts the occurrence of a clinically 
relevant inhibition of the adhesion of P-fimbriated E. coli to uroepithelial cells in humans. 
The Panel notes that no human studies from which conclusions could be drawn for the scientific 
substantiation of the claim were provided by the applicant. 
The  Panel  concludes  that  a  cause  and  effect  relationship  has  not  been  established  between 
the consumption of PAC in Urell® and reduction of bacterial colonisation of the urinary tract by 
inhibition of the adhesion of P-fimbriated E. coli to uroepithelial cells. 
CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
  The food product,  proanthocyanidins (PAC) in  Urell®, which is the subject of the health 
claim, is sufficiently characterised. 
  The  claimed  effect  is  “reduction  of  the  bacterial  colonisation  of  the  urinary  tract”,  and 
“inhibition of the adhesion of P-fimbriated E. coli to uroepithelial cells” is the mechanism by 
which the claim effect is achieved. The proposed target population is the general population. 
Reduction  of  bacterial  colonisation  of  the  urinary  tract  by  inhibition  of  the  adhesion  of 
P-fimbriated E. coli to uroepithelial cells is a beneficial physiological effect. PAC in Urell® and reduction of bacterial colonisation of the urinary tract  
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  A cause and effect relationship has not been established between the consumption of PAC in 
Urell® and reduction of bacterial colonisation of the urinary tract by inhibition of the adhesion 
of P-fimbriated E. coli to uroepithelial cells. 
DOCUMENTATION PROVIDED TO EFSA 
Health  claim  application  on  PAC  in  Urell®  pursuant  to  Article  13(5)  of  Regulation  (EC)  No 
1924/2006 (Claim serial No: 0358_FR). July 2012. Submitted by Pharmatoka. 
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GLOSSARY / ABBREVIATIONS 
AFSSAPS  Agence Francaise de Sécurité Sanitaire des Produits de Santé 
ANSES  L'Agence Nationale de Sécurité Sanitaire de l'Alimentation, de l’Environnement et du 
Traveil 
DGCCRF  Direction Générale de la Concurrence, de la Consommation et de la Répression des 
Fraudes  (French:  Directorate  General  for  Competition,  Consumer  Affairs  and 
Repression of Fraud) 
DMAC   4-dimethylaminocinnaldehyde 
EAU     European Association of Urology 
PAC    proanthocyanidins 
UTI    urinary tract infection 
WBC    white blood cells 